Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharma Mar SA (ES:PHM)
BME:PHM
Holding ES:PHM?
Track your performance easily
PHM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€26.16 - €86.40
Previous Close€78.3
Volume7.86K
Average Volume (3M)85.31K
Market Cap
€1.41B
Enterprise Value€1.27B
Total Cash (Recent Filing)C$182.42M
Total Debt (Recent Filing)C$42.63M
Price to Earnings (P/E)2218.1
Beta0.96
Next Earnings
Mar 03, 2025EPS Estimate
-€0.37Last Dividend Ex-Date
Jun 12, 2024Dividend Yield0.85%
Share Statistics
EPS (TTM)0.04
Shares Outstanding17,971,614
10 Day Avg. Volume81,631
30 Day Avg. Volume85,306
Standard Deviation0.17
R-Squared0.00782
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)6.31
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)18.80
P/FCF Ratio-41.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.00Price Target Upside-38.96% Downside
Rating ConsensusHold
Number of Analyst Covering1
Pharma Mar SA News
PremiumCompany Announcements
Pharma Mar S.A. Engages in Share Buy-Back Program
PremiumCompany Announcements
Pharma Mar SA Hits Recruitment Target in Key Cancer Trial
PremiumCompany Announcements
Pharma Mar Announces €5M Share Buy-Back Program
PremiumCompany Announcements
Pharma Mar S.A. Strengthens Corporate Governance
PremiumCompany Announcements
Pharma Mar Gains China Approval for Cancer Drug
PremiumCompany Announcements
Pharma Mar S.A. Reduces Share Capital by Canceling Shares
PremiumCompany Announcements
Pharma Mar Achieves Legal Win in Aplidin Case
PremiumCompany Announcements
Pharma Mar Hits $10 Million Milestone with JanssenOptions Prices
Currently, No data available
---
Ownership Overview
― Insiders
2.17% Mutual Funds
― Other Institutional Investors
94.44% Public Companies and
Individual Investors
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €26.16 and its highest was €86.40 in the past 12 months.
What is Pharma Mar SA’s market cap?
Currently, no data Available
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Mar 03, 2025 which is in 55 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Oct 29, 2024. The company reported €0.22 earnings per share for the quarter, beating the consensus estimate of €0.205 by €0.015.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Overvalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €0.526 which represents an annual dividend yield of 0.85%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is -€0.37.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,222,227 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.22 in its last earnings report, beating expectations of €0.205. Following the earnings report the stock price went up 0.603%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
---
Pharma Mar SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€48.00 (-38.96% Downside)
€48.00 (-38.96% Downside)
Insider Transactions
Bought Shares
Worth $352.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.75%
12-Months-Change
Fundamentals
Return on Equity
0.37%
Trailing 12-Months
Asset Growth
0.50%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
---
PHM Earnings Call
Q2 2024
0:00 / 0:00
---
PHM Stock 12 Month Forecast
Average Price Target
€48.00
▼(-38.96% Downside)
Technical Analysis
Best Analysts Covering PHM
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
+16.07%
reiterated a buy rating 9 months ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of +16.07% per trade.
---